Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Murcia – page 20

441 clinical trials in Murcia, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Murcia at a glance
441
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

441 trials in Murcia

Open in trial search

Colorectal cancer metastatic

Not recruiting

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Warm autoimmune haemolytic anaemia+1

Not recruiting

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Triple negative breast cancer

Not recruiting

A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Medica Scientia Innovation Research S.L.

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Malignant melanoma

Not recruiting

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Prostate cancer metastatic

Not recruiting

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Cystic fibrosis respiratory infection suppression

Not recruiting

Study of inhaled BX004 bacteriophage treatment for adults with cystic fibrosis who have chronic Pseudomonas aeruginosa lung infection

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IHMA-2121771-1
  • Sponsor:Biomx Ltd.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Murcia

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative clinical trials focusing on hematologic malignancies, including studies of new therapeutic combinations for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Research aims to evaluate novel treatment approaches and improve patient outcomes.

  • Chronic Myeloid Leukemia treatment optimization
  • Multiple Myeloma therapy combinations
  • Lymphoma management strategies
02 Solid Tumors

Comprehensive studies evaluating treatments for various solid tumors, including innovative approaches for breast cancer, melanoma, and gastric cancer. Research focuses on targeted therapies and immunotherapy combinations.

  • Advanced breast cancer treatments
  • Melanoma brain metastases therapy
  • Gastrointestinal cancer interventions
03 Neurological Conditions

Groundbreaking research in neurological disorders, particularly focusing on multiple sclerosis and acute cerebral ischemic stroke. Studies aim to evaluate new therapeutic agents and improve patient outcomes.

  • Stroke treatment innovations
  • Multiple sclerosis management
  • Neurological therapeutic advances
Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.